Physician profile
Ricardo Rey
NPI 1417049131
$15,872.12
in general payments reported to CMS, 2019-2025
59 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,586 · 2020: $1,644 · 2021: $2,171 · 2022: $2,285 · 2023: $2,617 · 2024: $2,317 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,107 · Gift: $59.40 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,106.87 |
| Gift | $59.40 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,250.69 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $1,837.85 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,342.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $905.82 | 2019-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $870.28 | 2019-2025 | |
| Lilly USA, LLC | $667.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $643.17 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $623.61 | 2019-2025 | Jardiance |
| Pfizer INC. | $455.50 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $452.84 | 2019-2022 | |
| Vifor Pharma, INC. | $452.34 | 2022-2025 | Veltassa |
| Kowa Pharmaceuticals America, INC. | $388.49 | 2019-2025 | Zoryve, Livalo |
| Corcept Therapeutics | $347.87 | 2023-2025 | Korlym |
| Ironwood Pharmaceuticals, INC | $339.71 | 2019-2024 | Linzess |
| Mannkind Corporation | $290.20 | 2019-2025 | Afrezza |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Rey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.